Montclair, California 91763

  • Alcoholic Fatty Liver Disease


This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB- 2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.


Inclusion Criteria: 1. Aged ≥ 18 years with a body mass index (BMI) ≤40 kg/m2. 2. Prior liver biopsy within 24 months of randomization with fibrosis Stage 1 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components: - Steatosis - Ballooning degeneration - Lobular inflammation AND - Confirmation of ≥ 8% liver fat content on MRI-PDFF. OR, if prior biopsy is not available: - Either overweight or obese or diabetic or ALT ≥ 30 U/L or fatty liver on ultrasound and at least one more feature of metabolic syndrome by Adult Treatment Panel III (ATP III) criteria. AND - Magnetic resonance elastography (MRE) ≥ 2.5 kPa and MRI-PDFF ≥ 8% during screening. Exclusion Criteria: Subjects meeting any of the following criteria are not eligible for enrollment in the study. 1. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening. Note: Significant alcohol consumption is defined as average of > 20 g/day in female subjects and > 30 g/day in male subjects. 2. Type 1 diabetes. 3. Uncontrolled Type 2 diabetes defined as: - HbA1c ≥ 9.5% during screening. (Subjects with HbA1c ≥ 9.5% may be rescreened). - Basal insulin dose adjustment > 10% within 60 days prior to enrollment. - Requirement for glucagon-like peptide analogue or a complex oral anti-diabetic (OAD) regimen (3 or more OADs) within 6 months of screening. - History of severe hypoglycemia (symptomatic hypoglycemia requiring outside assistance to regain normal neurologic status) within the previous year. Note: Individual diabetes regimens will be reviewed by Investigator and may be adjusted based on American Diabetes Association guidelines. 4. Presence of cirrhosis on liver biopsy (Stage 4 fibrosis) or imaging.



Primary Contact:

Principal Investigator
Rohit Loomba, MD

Study Director: Sagimet Biosciences Inc.
Phone: 650-561-8675

Backup Contact:


Location Contact:

Montclair, California 91763
United States

Rizawana Mohseni

Site Status: Recruiting

Data Source:

Date Processed: September 18, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.